{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:48:35Z","timestamp":1790812115978,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.pathol.2018.09.062","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T09:35:05Z","timestamp":1543829705000},"page":"131-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":149,"title":["Nonfasting versus fasting lipid profile for cardiovascular risk prediction"],"prefix":"10.1016","volume":"51","author":[{"given":"Anne","family":"Langsted","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-7220","authenticated-orcid":false,"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2018.09.062_bib1","first-page":"1093","article-title":"Plasma lipids in non-fasting patients and signal values of laboratory results. (Danish.)","volume":"171","author":"Nordestgaard","year":"2009","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.pathol.2018.09.062_bib2","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pathol.2018.09.062_bib3","series-title":"Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification. Clinical guideline [CG181]","year":"2014"},{"key":"10.1016\/j.pathol.2018.09.062_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.7326\/M15-0840","article-title":"Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 US Department of Veterans Affairs and US Department of Defense clinical practice guideline","volume":"163","author":"Downs","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pathol.2018.09.062_bib5","first-page":"1263","article-title":"2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pathol.2018.09.062_bib6","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pathol.2018.09.062_bib7","first-page":"569","article-title":"Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"32","author":"Leung","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pathol.2018.09.062_bib8","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pathol.2018.09.062_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.pathol.2018.09.062_bib10","first-page":"195","article-title":"Positioning about the flexibility of fasting for lipid profiling","volume":"108","author":"Scartezini","year":"2017","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.pathol.2018.09.062_bib11","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2018.09.062_bib12","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2018.09.062_bib13","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.pathol.2018.09.062_bib14","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.pathol.2018.09.062_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.pathol.2018.09.062_bib16","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1161\/01.CIR.101.16.1907","article-title":"Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene","volume":"101","author":"Agerholm-Larsen","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pathol.2018.09.062_bib17","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1001\/jama.299.21.2524","article-title":"Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease","volume":"299","author":"Frikke-Schmidt","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.pathol.2018.09.062_bib18","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2018.09.062_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2018.09.062_bib20","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1161\/ATVBAHA.113.301373","article-title":"Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks","volume":"33","author":"Li","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pathol.2018.09.062_bib21","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2018.09.062_bib22","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","article-title":"Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies","volume":"38","author":"Madsen","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pathol.2018.09.062_bib23","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/eurheartj\/ehx665","article-title":"U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies","volume":"39","author":"Madsen","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pathol.2018.09.062_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"Jorgensen","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2018.09.062_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2018.09.062_bib26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1373\/clinchem.2013.219881","article-title":"Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study","volume":"60","author":"Thomsen","year":"2014","journal-title":"Clin Chem"},{"key":"10.1016\/j.pathol.2018.09.062_bib27","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2018.09.062_bib28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.pathol.2018.09.062_bib29","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Group","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2018.09.062_bib30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2008.10.024","article-title":"Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk","volume":"53","author":"Robinson","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.pathol.2018.09.062_bib31","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.pathol.2018.09.062_bib32","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.pathol.2018.09.062_bib33","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1373\/clinchem.2008.117929","article-title":"Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women","volume":"55","author":"Mora","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.pathol.2018.09.062_bib34","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.cca.2010.07.034","article-title":"Comparison of low-density lipoprotein cholesterol concentrations measured by a direct homogeneous assay and by the Friedewald formula in a large community population","volume":"411","author":"Tanno","year":"2010","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.pathol.2018.09.062_bib35","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pathol.2018.09.062_bib36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City heart study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pathol.2018.09.062_bib37","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2018.09.062_bib38","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.pathol.2018.09.062_bib39","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.pathol.2018.09.062_bib40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1373\/clinchem.2008.118356","article-title":"Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices","volume":"55","author":"Contois","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.pathol.2018.09.062_bib41","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1161\/01.ATV.0000255580.73689.8e","article-title":"Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study","volume":"27","author":"Benn","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pathol.2018.09.062_bib42","first-page":"2499","article-title":"Lipid-related markers and cardiovascular disease prediction","volume":"307","author":"Di Angelantonio","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.pathol.2018.09.062_bib43","first-page":"214","article-title":"Lipoprotein biomarkers and risk of cardiovascular disease: a Laboratory Medicine Best Practices (LMBP) systematic review","volume":"1","author":"Sandhu","year":"2016","journal-title":"J\u00a0Appl Lab Med"},{"key":"10.1016\/j.pathol.2018.09.062_bib44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A\u00a0meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.pathol.2018.09.062_bib45","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/ATVBAHA.114.304349","article-title":"Use of lipoprotein particle measures for assessing coronary heart disease risk post-American Heart Association\/American College of Cardiology guidelines: the multi-ethnic study of atherosclerosis","volume":"35","author":"Steffen","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pathol.2018.09.062_bib46","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1373\/clinchem.2018.287037","article-title":"Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM","volume":"64","author":"Langlois","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.pathol.2018.09.062_bib47","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1042\/CS20070265","article-title":"Non-HDL cholesterol and apoB in dyslipidaemia","volume":"114","author":"Sniderman","year":"2008","journal-title":"Clin Sci"},{"key":"10.1016\/j.pathol.2018.09.062_bib48","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.jacc.2017.08.006","article-title":"A\u00a0test in context: lipid profile, fasting versus nonfasting","volume":"70","author":"Nordestgaard","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.pathol.2018.09.062_bib49","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"2705","article-title":"Introduction: structure and metabolism of plasma lipoproteins","author":"Havel","year":"2001"},{"key":"10.1016\/j.pathol.2018.09.062_bib50","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","article-title":"Mechanisms of plaque formation and rupture","volume":"114","author":"Bentzon","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.pathol.2018.09.062_bib51","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.amjmed.2016.10.022","article-title":"Current understanding of atherogenesis","volume":"130","author":"Brown","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.pathol.2018.09.062_bib52","first-page":"137","article-title":"Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels","volume":"35","author":"Gronholdt","year":"2002","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.pathol.2018.09.062_bib53","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.ATV.20.5.1177","article-title":"Natural history and histological classification of atherosclerotic lesions: an update","volume":"20","author":"Stary","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pathol.2018.09.062_bib54","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/01.ATV.15.9.1512","article-title":"A\u00a0definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association","volume":"15","author":"Stary","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pathol.2018.09.062_bib55","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1177\/153537020422900611","article-title":"Differential effects of low-density lipoprotein and chylomicron remnants on lipid accumulation in human macrophages","volume":"229","author":"Batt","year":"2004","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.pathol.2018.09.062_bib56","doi-asserted-by":"crossref","first-page":"200","DOI":"10.5551\/jat.11.200","article-title":"The very low-density lipoprotein (VLDL) receptor: characterization and functions as a peripheral lipoprotein receptor","volume":"11","author":"Takahashi","year":"2004","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.pathol.2018.09.062_bib57","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1161\/01.ATV.8.4.421","article-title":"Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall","volume":"8","author":"Nordestgaard","year":"1988","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.pathol.2018.09.062_bib58","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0022-2275(20)38428-5","article-title":"Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits","volume":"29","author":"Nordestgaard","year":"1988","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.pathol.2018.09.062_bib59","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.pathol.2018.09.062_bib60","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.108.804146","article-title":"Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction","volume":"118","author":"Langsted","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pathol.2018.09.062_bib61","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1373\/clinchem.2010.157164","article-title":"Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58,434 individuals from the Copenhagen General Population Study","volume":"57","author":"Langsted","year":"2011","journal-title":"Clin Chem"},{"key":"10.1016\/j.pathol.2018.09.062_bib62","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.108.777334","article-title":"Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events","volume":"118","author":"Mora","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pathol.2018.09.062_bib63","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/archinternmed.2012.3708","article-title":"Fasting time and lipid levels in a community-based population: a cross-sectional study","volume":"172","author":"Sidhu","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pathol.2018.09.062_bib64","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1542\/peds.2011-0844","article-title":"Fasting might not be necessary before lipid screening: a nationally representative cross-sectional study","volume":"128","author":"Steiner","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.pathol.2018.09.062_bib65","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2014.01.049","article-title":"Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk","volume":"234","author":"Langsted","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pathol.2018.09.062_bib66","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/CIRCULATIONAHA.114.010001","article-title":"Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III)","volume":"130","author":"Doran","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pathol.2018.09.062_bib67","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pathol.2018.09.062_bib68","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1001\/jama.2008.621","article-title":"Nonfasting triglycerides and risk of ischemic stroke in the general population","volume":"300","author":"Freiberg","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.pathol.2018.09.062_bib69","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1093\/eurheartj\/ehr333","article-title":"The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK","volume":"32","author":"Sever","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pathol.2018.09.062_bib70","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2018.09.062_bib71","article-title":"Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors","volume":"154","author":"Bowman","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.pathol.2018.09.062_bib72","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0022-2275(20)38520-5","article-title":"Postprandial plasma lipoprotein changes in human subjects of different ages","volume":"29","author":"Cohn","year":"1988","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.pathol.2018.09.062_bib73","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0002-9149(01)02047-1","article-title":"Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease","volume":"88","author":"Schaefer","year":"2001","journal-title":"Am J Cardiol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302518303003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302518303003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:24:01Z","timestamp":1758471841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302518303003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0031302518303003"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2018.09.062","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonfasting versus fasting lipid profile for cardiovascular risk prediction","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2018.09.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}